[Long-term results of small cell lung cancer treated by surgical resection and multimodality therapy].
241 patients with small cell lung cancer (SCLC) were operated in our hospital from 1957 to 1985. The early postoperative mortality was 1.7%. The 5-yr survival rate was 23.2% (56/241). The 10-yr survival rate was 16.5% (15/91) (only 4 patients died during 5-yr to 10-yr after surgery but none of them died of SCLC). We analysed the 5-yr survival group. The 5-yr survival rate for stage I patients was 52.3% (23/44), stage II 34.1% (14/41), stage III 12.8% (19/149) [IIIa12.3% (17/138),IIIb 18.2% (2/11)]. Stage IV 0 (0/3). The P value: I vs IIIaP < 0.001, II vs IIIaP < 0.01. 125 patients received chemotherapy (CT) and/or radiotherapy (RT) postoperatively (group A) and the other 112 cases received surgical resection only (group B). 4 patients (3 IIIa, 1 IIIb) who died in early postoperative period were not counted. The 5-yr survival rate for group A and B was 40.8% (51/125) and 4.5% (5/112) respectively, P < 0.001; for group A and B stage I was 71.4% (20/28) and 18.8% (3/16), P < 0.01;for group A and B stage II was 54.5% (12/22) and 10.5% (2/19), P < 0.01; for group A and B stage IIIa was 25.4% (17/67) and 0 (0/71), P < 0.001. There were no differences in 5-yr survival rate on types of surgical resection and locations of the disease. The present results revealed that the total 5-yr survival rate for SCLC was 23.2%, among them for resection only was 4.5% and for resection plus multimodality therapy was 40.8%.(ABSTRACT TRUNCATED AT 250 WORDS)
Xu
J Z
JZ
Thoracic Tumor Institute and Hospital, Bei jing.
D000328:Adult; D000368:Aged; D018288:Carcinoma, Small Cell / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D015996:Survival Rate